Analysts' Top 5 Price Targets of July 2, 2025
Reading Time: 3 minutes
aTyr Pharma [US0021202025]: Wells Fargo confirms Buy rating with a price target of $25 (386% upside potential) Wells Fargo has issued a buy recommendation for aTyr Pharma's stock, as experts see significant potential in the drug candidate Efzofitimod, which is currently being tested in a Phase 3 study for the treatment of pulmonary sarcoidosis. The release of the topline results is expected between July and September 2025. Wells Fargo's confidence is based on several factors: previous study data has been promising and has reduced the risk of failure....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
